A new category of immunotherapies called checkpoint inhibitors that has been highly effective against many different cancers appears safe to use in patients with both advanced malignancies and HIV, a population excluded from ...
Nov 7, 2017
0
9
U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults.
Oct 19, 2017
0
65
Researchers from the University of Southampton have identified why some people may become resistant to monoclonal antibodies, a common type of immunotherapy used in lymphoma treatment.
Jul 14, 2017
0
1
Today some patients suffering with mantle cell lymphoma, a type of blood cancer, can be treated with a pill called Ibrutinib, forgoing conventional chemotherapy. However, many are developing a resistance to this treatment. ...
Jun 14, 2017
0
18
A University of Queensland researcher has found patients with non-hodgkins lymphoma are most likely to survive if they have a rich variety of T-cells.
Apr 3, 2017
0
51
An important regulator that controls the ability of tumour cells to hide from the immune system in lymphoma patients, making them unlikely to respond to standard treatment, has been discovered by scientists at the University ...
Oct 30, 2015
0
10
A University of Kentucky study shows that withaferin A, a component of Withania somnifera (winter cherry) plant extract, may hold promise as a new treatment for non-Hodgkin's lymphoma.
Sep 14, 2015
0
323
The goal for many cancer patients is to reach the five-year, disease-free mark, but new research from UR Medicine's Wilmot Cancer Institute suggests that two years might be a more practical survival goal for people with follicular ...
Jun 29, 2015
0
14
In a late-stage clinical trial, Hodgkin lymphoma (HL) patients who received brentuximab vedotin (BV) post-transplant lived longer without disease progression than patients who received only supportive care. This is the first ...
Dec 6, 2014
0
0
Patients with B-cell Non-Hodgkin lymphomas and advanced solid tumours have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial.
Nov 20, 2014
0
0
